PLRX Earnings & Financial Statements
Pliant Therapeutics, Inc.
$0.95
+$0.06(+7.10%)
33
Overall
60
Value
18
Tech
23
Quality
Market Cap
$54.73M
Volume
313.95K
52W Range
$0.97 - $1.95
Target Price
$2.50
PLRX earnings and financial statements: Pliant Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PLRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $1.58M | $9.69M | $7.57M |
| Operating income | -$156.37M | -$228.37M | -$184.15M | -$127.20M | -$97.53M |
| EBITDA | -$141.81M | -$201.73M | -$162.14M | -$120.68M | -$95.73M |
| Net income | -$149.34M | -$210.30M | -$161.34M | -$123.32M | -$97.26M |
| EPS (diluted) | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $225.23M | $396.95M | $512.15M | $350.61M | $221.22M |
| Total liabilities | $44.02M | $92.87M | $38.58M | $37.27M | $22.16M |
| Shareholders’ equity | $181.21M | $304.08M | $473.58M | $313.34M | $199.06M |
| Cash and equivalents | $45.45M | $71.19M | $63.23M | $33.69M | $51.66M |
| Long-term debt | $27.66M | $59.65M | $10.05M | $13.36M | $5.33M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$128.34M | -$155.50M | -$116.36M | -$94.63M | -$75.44M |
| Capital expenditure | -$219.0K | -$3.85M | -$921.0K | -$1.76M | -$1.95M |
| Free cash flow | -$128.71M | -$159.35M | -$117.28M | -$96.39M | -$77.40M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PLRX | $0.95 | +7.1% | 313.95K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Pliant Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW